The C2 CryoBalloon System is set to revolutionize esophageal lesion treatment in Japan. The device offers precise cryoablation for enhanced patient care.

IceCure Medical (ICCM) completed the first patient treatment in its ChoICE post-marketing study evaluating ProSense cryoablation for low-risk breast cancer.The patient was enrolled and treated at West Cancer Center & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine. Cryoablation destroys tumors by freezing. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data within ProSense's FDA-cleared indication. IceCure expects participating sites to operate as both study centers and commercial sites, offering treatment to eligible patients outside the study.

For locally advanced pancreatic cancer, cryoablation plus drug treatment was linked to longer median survival than drug treatment alone, but the result does not prove benefit. Among 186 patients, median survival was 22.1 months with combined treatment, versus 17.8 months with drug treatment alone. C

Reported Tuesday, Oct 27 - 8:35am EDT (TheFly subscription required to read more.)

KUCHING (Oct 30): The Sarawak Heart Centre has become the first hospital in Southeast Asia to perform convergence procedure for left atrial ablation. A post on the centre’s Facebook page said it also ...

Reported Tuesday, Oct 20 - 7:57am EDT (TheFly subscription required to read more.)

IceCure Medical (ICCM) enrolled the first two patients at U.S. sites in its ChoICE post-marketing study of ProSense breast cancer cryoablation. The study evaluates local treatment of low-risk breast cancer using freezing to destroy tumors. The patients were enrolled at West Cancer Center & Research Institute in Germantown, Tennessee, and Adventist Health Glendale in California.ChoICE is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites, generating real-world data within ProSense's FDA-cleared indication. Both initial sites received institutional review board approval and signed site agreements before becoming eligible to enroll patients in August 2026. Legacy Health's Good Samaritan Medical Center in Portland, Oregon, joined the network earlier this month. IceCure expects participating centers to also operate as commercial sites, treating eligible patients outside the study.

In Australia imaging is becoming a tool for healing Australia has introduced an advanced MRI-guided cryoablation system at Liverpool Hospital in southwest Sydney, giving doctors a more precise way to...

At EUSOBI 2026, IceCure Medical presented impressive clinical data for ProSense® cryoablation, demonstrating strong physician engagement and successful outcomes.

IceCure Medical (Nasdaq: ICCM) presented ProSense breast cancer cryoablation clinical data at the European Society of Breast Imaging’s 2026 annual meeting.Presentations reported 12-month objective response rates, a measure of tumor response, of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone. Cryoablation destroys tumors by freezing. The meeting took place in Maastricht, the Netherlands.ProSense featured in two scientific sessions, including findings on elderly breast cancer patients ineligible for surgery. IceCure hosted two clinical workshops, each attracting nearly 70 participants. Two posters by ProSense users addressed one-year outcomes for breast lesions in Romania and imaging to predict tissue response after breast cryoablation.

Researchers propose the Lethal Isotherm Ratio, a standardized metric showing how much of a visible cryoablation ice ball is actually cold enough to kill tumor cells.

The Cryoablation EP Catheter Market is expected to grow from 2,600 USD Million in 2025 to 5 USD Billion by 2035. The Cryoablation EP Catheter Market CAGR (growth rate) is expected to be around 6.6% | ...